The Disease Management Project Breast Cancer (DMP Breast Cancer) was first launched in Hesse in 2004. The project is supported by the health insurance companies in Hesse and the Professional Association of Gynaecologists in Hesse. The aim is to offer structured treatment programmes to all women diagnosed with breast cancer in Hesse by creating intersectoral cooperations between coordinating clinics, associated hospitals and gynaecologists in private practice who registered in the DMP programme. Method: Between 1 January 2005 and 30 June 2011, 13 973 women were enrolled in the DMP programme. Results: After data cleansing, survival rates were calculated for a total of 11 214 women. The 5-year overall survival (OS) rate was 86.3 %; survival rates according to tumour stage on presentation were 92.2 % (pT1) and 82.3 % (pT2), respectively. The impact of steroid hormone receptor status on survival (87.8 % for receptor-positive cancers vs. 78.9 % for receptor-negative cancers) and of age at first diagnosis on survival (≤ 35 years = 91 %) were calculated. Conclusion: The project showed that intersectoral cooperation led to significant improvements in the quality of treatment over time, as measured by quality indicators and outcomes after treatment.
Centres of Excellence, all DMP partners in Hesse and the results of the Agency for Quality Assurance (Geschäftsstelle für Qualitätssicherung, GQH).
History of the DMP Hesse
Prior to the start of the DMP programme in Hesse and the structured dialogue programme (Operative Gynäkologie Hessen [Surgical Gynaecology Hesse]) for quality assurance of the GQH, breast cancer treatment in Hesse varied greatly. Around 4000 cases underwent surgical treatment in one of Hesseʼs 80 hospitals every year. Facilities and equipment differed widely between hospitals. 70 % of hospitals carried out fewer than 50 breast cancer operations per year. Only 8 % of hospitals carried out at least 150 operations annually. These hospitals treated almost 39 % of all new cases. The structured treatment programme for breast cancer patients in Hesse was approved by the German Federal Social Insurance Authority (Bundesversicherungsamt) on January 
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Coordinating and cooperating hospitalscreating the perfect network
In this model, a hospital can conclude a framework agreement and is then responsible for coordinating activities in a regional breast centre of excellence. The agreement ensures that surgical standards and standards for adjuvant therapy are complied with, that more breast-conserving surgeries are carried out, and that patients are comprehensively followed up and given psychosocial support. Joint case conferences and at least two DMP training courses per year improve quality management (including optimising interfaces between facilities) and training. A network of interdisciplinary healthcare services and breast centres of excellence was developed. Coordinating hospitals were "high-volume" hospitals with more than 150 new cases treated annually. Coordinating and cooperating hospitals integrated in a centre of excellence had to show that each surgeon had previously carried out at least 50 breast cancer operations (l " Fig. 1 ). Breast centres of excellence also include DMP-accredited gynaecologists, who are primarily responsible for outpatient treatment and followup care (l " Fig. 2 ). The Gemeinsame Einrichtung (GE), a body composed of equal numbers of representatives from hospitals in Hesse, representatives from the breast centres of excellence and from the Professional Association of Gynaecologists in Hesse, is responsible for quality assurance. Common quality indicators were defined for all DMP hospitals. Comprehensive coverage through the creation of an intersectoral network and an annual anonymised evaluation assessing compliance with quality was achieved in Hesse [1] , with GQH employees providing regular feedback of results to healthcare providers.
Current situation
The programme kicked off on January 1, 2004. Nine breast centres of excellence with 34 participating hospitals and more than 500 affiliated physicians in private practice were set up across the state of Hesse to offer comprehensive healthcare coverage. This created the basic structure with interdisciplinary on- cological conferences and structured follow-up care provided by local affiliated gynaecologists. 564 gynaecologists out of a total 700 of gynaecological practices in Hesse joined the programme, ensuring that outpatient and follow-up care was available to every patient enrolled in the DMP programme (data from December 2012). Just under 3500 patients were enrolled in the DMP programme in one year. Surgical quality assurance data were compared and analysed using data from non-DMP hospitals as a benchmark to evaluate whether the objectives of the DMP programme were being achieved. The GQH report for the years 2004-2006 (initial registration) shows the improvements over time for the 18 quality indicators (l " Fig. 3 ). The data from 2010 show considerable changes (l " Fig. 4 ). In the early years of 2004-2006, there were considerable differences between DMP hospitals and non-DMP hospitals with regard to achieving quality indicators. When the rates of breastconserving surgeries for pT1 tumours were compared, the rates for non-DMP hospitals were around 10 % lower. Since then, com-bined quality controls have greatly reduced this disparity. Fortunately, the quality indicators are distributed uniformly across all of the centres of excellence. At the start of the DMP programme, preoperative knowledge of the definitive histology of invasive carcinomas was > 70% in the centres of excellence, while the rate for this indicator in non-DMP hospitals was < 30 %. Today, the overall figures are > 98 % (for DMP hospitals) and 90.6 % (for non-DMP hospitals). records compiled by DMP hospitals. Data on tumour size (pT1-pT4) and hormone receptor status were additionally included in the analysis (l " Fig. 5 ).
Material and Method
The following treatment-relevant clinical endpoints were calculated: " Total survival " Total survival according to tumour stage at presentation " Total survival according to hormone receptor status " Total survival according to age distribution Cox proportional hazards model and log-rank test were used for statistical analysis. The high quality of the data is due to the fact that on 30th June 2011, the cut-off date of the survey, 86.7 % of registered women were reported to be alive with only 8.3 % reported to have died during survey period. 5% (557 women) were removed from the analysis as "lost to follow up".
Results
!
5-year survival rate
Survival was calculated in months from the date of the first manifestation of the primary tumour in the reference period. Fiveyear overall survival (OS) for the evaluated 11 214 women calculated across all age groups and irrespective of tumour stage at diagnosis was 86.3 % (l " Fig. 6 ).
5-year survival rate according to tumour stage
Tumour stage or size was not specified in 1694 cases, leaving a total of 9520 cases available for analysis. For the evaluation period, it could be shown that when tumour diameters were ≤ 2 cm (pT1), there was an excellent 5-year survival rate of 92.2 %. Even for women with larger tumours (2-5 cm; pT2) the survival rate was still an impressive 82.3 % (l " Fig. 7 ). Fig. 7 Overall survival according to tumour stage.
Basic data from DMP Breast Cancer Hesse
5-year survival rate according to hormone receptor status
Hormone receptor status (oestrogen and progesterone) is an important prognostic and predictive factor for anti-hormone treatment. The data of 11 213 women were available for analysis. The available data did not permit a differentiation between oestrogen receptor (ER) and progesterone receptor (PR) status. The analysis therefore only included the indicator "positive hormone receptor status". The 5-year survival rate for women with hormone receptor-positive breast cancer was 87.8 versus 78.9 % for women with hormone receptor-negative tumours (l " Fig. 8 ). Analysis did not take into account whether patients underwent anti-hormone therapy.
5-year survival rate according to age at diagnosis
Although breast cancer is more common among older women, increasing numbers of younger women have also been diagnosed with this disease in the last few years. Younger age at diagnosis is an unfavourable prognostic factor. This makes the results presented here on survival rates according to age at diagnosis even more interesting. Rates were calculated based on the data of 10 657 women. The 5-year survival rate of 91 % calculated for women ≤ 35 years was particularly noteworthy (l " Fig. 9 ).
Discussion
!
In an age of evidence-based medicine, comparatively little information is available on routine medical care available for oncological disease [2] . Particularly for breast cancer, the most common malignant disease affecting the female population with an incidence of almost 72 000 new cases every year, there are only limited reliable data. Only the Robert Koch Institute (RKI) with its current summary of epidemiological data for the years 2007/8 offers a good overview [3] . The current RKI review reports an absolute overall 5-year survival rate of 78.0 % for 2007/8 [3] . This means that our figure of 86. In contrast, the rates are more favourable in the Bavarian population for women older than 60 years of age [9] . The continued increase in the incidence of breast cancer in women has been variously ascribed to the adoption of an "urban lifestyle", possible in combination with a fundamental change in the reproductive behaviour of the female population. As mammography screening has become increasingly common and systemic adjuvant therapymainly the use of tamoxifenhas begun to have an impact, there has been a so-called "stage shift" of tumour stage at diagnosis, and mortality has dropped. This shift has been particularly noticeable in women with breast cancer and a positive oestrogen receptor status (ER pos.) and women younger than 70 years of age at the time of diagnosis. It would appear that oestrogen receptor-negative (ER neg.) breast cancers are more common at a younger age than ER-positive tumours. The incidence of ER-negative cancer first plateaus at around 50 years of age, and at around 70 years for ER-positive cancers. Loco-regional control has also improved as investigation of surgical specimens has improved and use of radiation therapy has become more common [4] . Analysis of parameters was deliberately limited to data collected for the classic prognostic factors (age, tumour size and hormone receptor status data can now be used as a basis for a more detailed analysis of treatment results after breast cancer therapy and can be compared with comparative national and international studies. It could also be shown that intersectoral cooperation between the clinical sectors offering acute care and gynaecologists who provide diagnosis and follow-up outside the hospitals has improved the quality of outcomes. It is well known that the quality of treatment and care provided to women with breast cancer is positively correlated to structures, specialisation and experience. When this was measured using the numbers of patients receiving surgery after their first diagnosis for every hospital ("hospital" or "surgeonsʼ volume"), data for the state of New Yorkwhich has a similarly heterogeneous population distribution and hospitals with a wide variability in cases with primary diseaseclearly proved the connection between the number of patients with primary disease who underwent surgery and 5-year survival rates [5] . With regard to 5-year survival, Roohan et al. were able to show that hospitals with more than 150 primary cases every year had an advantage of 30 % compared to hospitals which cared for fewer than 50 primary cases per year. This still applied for comorbidities and lymph node involvement after adjusted multivariate analysis [5] . Another positive side effect was that compliance with quality indicators also improved in non-DMP hospitals in Hesse. In one of the first analyses on the effect of the DMP project in Hesse, du Bois et al. were able to show already in 2004 that the quality of outcomes after treatment offered to breast cancer patients in Hesse varied greatly with regard to rates of breast-conserving surgeries. One of the original DMP criteria was a figure of at least 50 primary operations in every DMP hospital [6] . These structural conditions are also a basic requirement of guidelines-based systemic therapy [7, 8] . A lot has been achieved with the DMP in Hesse in the last few years; all parties participating in the intersectoral network must maintain this motivation when providing care to women with breast cancer in hospitals and in doctorsʼ practices. Patients and their families and the general population without disease have a right to know where high-quality evidence-based medical care is available [10, 11] . Cooperations between different facilities to implement and improve quality indicators and guidelines are instruments which can be used to continually optimise therapy [12] . Certified breast centres have been established in Germany since many years as models which show how care can be optimised [13] .
